{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T07:21:05Z","timestamp":1747207265104,"version":"3.40.5"},"reference-count":32,"publisher":"Bentham Science Publishers Ltd.","issue":"8","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CCDT"],"published-print":{"date-parts":[[2020,9,4]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Egypt is one of the highest hepatitis C virus (HCV) endemic areas. Chronic\nHCV infection has extra-hepatic manifestations, including non-Hodgkin lymphoma (NHL). Diffuse\nlarge B-cell lymphoma (DLBCL) is commonly associated with HCV infection. The prognostic value\nof HCV infection and HCV treatment in patients with DLBCL remains unclear until now.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>The aim of our study is to evaluate the impact of HCV infection and HCV treatment as\nindependent prognostic factors on the event-free survival (EFS) and overall survival (OS) in Egyptian\npatients with HCV associated DLBCL.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>This study included 353 patients with DLBCL, collected retrospectively. While 34 patients\nwith HCV who received HCV antiviral therapy were collected prospectively. Patient\u2019s characteristics\nwere collected from the patient records at the time of diagnosis. The status of the patients\nabout HCV infection and HCV treatment were also recorded. Disease progression, relapse, retreatment\nor deaths were also verified through medical records. EFS and OS were calculated.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>EFS and OS significantly decrease in HCV infected and HCV non-treated patients when\ncompared with HCV non-infected and HCV treated patients, respectively. HCV infection but not\nHCV treatment was independently associated with EFS and OS using univariate and multivariate\nanalysis.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Hepatitis C virus infection is an independent prognostic factor for EFS and OS in diffuse\nlarge B-cell lymphoma. HCV treatment is associated with higher EFS and OS but can not be\nconsidered as an independent prognostic factor.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1568009620666200511084731","type":"journal-article","created":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T19:54:23Z","timestamp":1589226863000},"page":"638-645","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Hepatitis C Virus Infection and Treatment as Independent Prognostic Factors in Diffuse Large B-Cell Lymphoma Egyptian Patients"],"prefix":"10.2174","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8605-5384","authenticated-orcid":true,"given":"Tamer A.","family":"Elbedewy","sequence":"first","affiliation":[{"name":"Internal Medicine Department, Faculty of Medicine, Tanta University, Tanta, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3134-8117","authenticated-orcid":true,"given":"Hossam Eldin A.","family":"Elashtokhy","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Tanta Cancer Center, Tanta, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4366-2218","authenticated-orcid":true,"given":"Sherief","family":"Abd-Elsalam","sequence":"additional","affiliation":[{"name":"Tropical Medicine Department, Tanta University, Tanta, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2225-3098","authenticated-orcid":true,"given":"Marwa A.","family":"Suliman","sequence":"additional","affiliation":[{"name":"Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Suez Canal University, Al Ismailia, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1002\/hep.22759","volume":"49","author":"Ghany M.G.","year":"2009","unstructured":"Ghany M.G.; Strader D.B.; Thomas D.L.; Seeff L.B.; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: An update. Hepatology 2009,49(4),1335-1374","journal-title":"Hepatology"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1016\/j.jhep.2014.07.027","volume":"61","author":"Gower E.","year":"2014","unstructured":"Gower E.; Estes C.; Blach S.; Razavi-Shearer K.; Razavi H.; Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014,61(1)(Suppl.),S45-S57","journal-title":"J Hepatol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ajg.2014.04.003","volume":"15","author":"Waked I.","year":"2014","unstructured":"Waked I.; Doss W.; El-Sayed M.H.; Estes C.; Razavi H.; Shiha G.; Yosry A.; Esmat G.; The current and future disease burden of chronic hepatitis C virus infection in Egypt. Arab J Gastroenterol 2014,15(2),45-52","journal-title":"Arab J Gastroenterol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2147\/IDR.S153060","volume":"11","author":"Ahmed O.A.","year":"2018","unstructured":"Ahmed O.A.; Kaisar H.H.; Badawi R.; Hawash N.; Samir H.; Shabana S.S.T.; Fouad M.H.A.; Rizk F.H.; Khodeir S.A.; Abd-Elsalam S.; Efficacy and safety of sofosbuvir-ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection. Infect Drug Resist 2018,11,295-298","journal-title":"Infect Drug Resist"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"5459","DOI":"10.1007\/s11356-017-0897-y","volume":"25","author":"Abdelmoemen G.","year":"2018","unstructured":"Abdelmoemen G.; Khodeir S.A.; Abou-Saif S.; Kobtan A.; Abd-Elsalam S.; Prevalence of occult hepatitis C virus among hemodialysis patients in Tanta University Hospitals: A single-center study. Environ Sci Pollut Res Int 2018,25(6),5459-5464","journal-title":"Environ Sci Pollut Res Int"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1002\/1529-0131(199910)42:10<2204:AID-ANR24>3.0.CO;2-D","volume":"42","author":"Cacoub P.","year":"1999","unstructured":"Cacoub P.; Poynard T.; Ghillani P.; Charlotte F.; Olivi M.; Piette J.C.; Opolon P.; MULTIVIRC Group Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment virus C. Arthritis Rheum 1999,42(10),2204-2212","journal-title":"Arthritis Rheum"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1158\/1055-9965.EPI-06-0308","volume":"15","author":"Dal Maso L.","year":"2006","unstructured":"Dal Maso L.; Franceschi S.; Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies. Cancer Epidemiol Biomarkers Prev 2006,15(11),2078-2085","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"5119","DOI":"10.1182\/blood-2010-06-289231","volume":"116","author":"Ennishi D.","year":"2010","unstructured":"Ennishi D.; Maeda Y.; Niitsu N.; Kojima M.; Izutsu K.; Takizawa J.; Kusumoto S.; Okamoto M.; Yokoyama M.; Takamatsu Y.; Sunami K.; Miyata A.; Murayama K.; Sakai A.; Matsumoto M.; Shinagawa K.; Takaki A.; Matsuo K.; Kinoshita T.; Tanimoto M.; Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: A Japanese multicenter analysis. Blood 2010,116(24),5119-5125","journal-title":"Blood"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1093\/ije\/dyh183","volume":"33","author":"Cowgill K.D.","year":"2004","unstructured":"Cowgill K.D.; Loffredo C.A.; Eissa S.A.; Mokhtar N.; Abdel-Hamid, M.; Fahmy, A.; Strickland, G.T. Case-control study of non-Hodgkin\u2019 lymphoma and hepatitis C virus infection in Egypt. Int J Epidemiol 2004,33(5),1034-1039","journal-title":"Int J Epidemiol"},{"key":"ref=10","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/429784","author":"Youssef S.S.","year":"2012","unstructured":"Youssef S.S.; Nasr A.S.; El Zanaty T.; El Rawi R.S.; Mattar M.M.; Prevalence of occult hepatitis C virus in egyptian patients with chronic lymphoproliferative disorders. Hepat Res Treat 2012","journal-title":"Hepat Res Treat"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"17","DOI":"10.21608\/aeji.2013.17092","volume":"3","author":"Abu-Taleb F.","year":"2013","unstructured":"Abu-Taleb F.; El-Hefni A.; Kotb A.; El-Gohary T.A.; Efficacy of ribavirin to prevent hepatitis reactivation in hepatitis C virus infected patients treated for non-Hodgkin lymphoma. Afro-Egypt J. Infect Endem Dis 2013,3(1),17-26","journal-title":"Infect Endem Dis"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1002\/hep.25499","volume":"55","author":"Hartridge-Lambert S.K.","year":"2012","unstructured":"Hartridge-Lambert S.K.; Stein E.M.; Markowitz A.J.; Portlock C.S.; Hepatitis C and non-Hodgkin lymphoma: The clinical perspective. Hepatology 2012,55(2),634-641","journal-title":"Hepatology"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1200\/JCO.2005.01.5016","volume":"24","author":"Besson C.","year":"2006","unstructured":"Besson C.; Canioni D.; Lepage E.; Pol S.; Morel P.; Lederlin P.; Groupe d\u2019Etude des Lymphomes de l\u2019Adulte Programs. Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Grouped\u2019Etude des Lymphomes de l\u2019Adulte programs. J Clin Oncol 2006,24(6),953-960","journal-title":"J Clin Oncol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1093\/annonc\/mdl131","volume":"17","author":"Visco C.","year":"2006","unstructured":"Visco C.; Arcaini L.; Brusamolino E.; Burcheri S.; Ambrosetti A.; Merli M.; Bonoldi E.; Chilosi M.; Viglio A.; Lazzarino M.; Pizzolo G.; Rodeghiero F.; Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: Analysis of 156 patients from northern Italy. Ann Oncol 2006,17(9),1434-1440","journal-title":"Ann Oncol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1093\/annonc\/8.suppl_2.S11","volume":"8","author":"Harris N.L.","year":"1997","unstructured":"Harris N.L.; Principles of the revised European\u2013American lymphoma classification (from the International Lymphoma Study Group). Ann Oncol 1997,8(Suppl. 2),11-16","journal-title":"Ann Oncol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"Cheson B.D.","year":"1999","unstructured":"Cheson B.D.; Horning S.J.; Coiffier B.; Shipp M.A.; Fisher R.I.; Connors J.M.; Lister T.A.; Vose J.; Grillo-L\u00f3pez A.; Hagenbeek A.; Cabanillas F.; Klippensten D.; Hiddemann W.; Castellino R.; Harris N.L.; Armitage J.O.; Carter W.; Hoppe R.; Canellos G.P.; NCI Sponsored International Working Group Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. J Clin Oncol 1999,17(4),1244","journal-title":"J Clin Oncol"},{"key":"ref=17","doi-asserted-by":"publisher","DOI":"10.2174\/1871526519666190121114003","author":"Mohamed A.A.","year":"2019","unstructured":"Mohamed A.A.; El-Toukhy N.E.R.; Said E.M.; Gabal H.M.R.; AbdelAziz H.; Doss W.; El-Hanafi H.; El Deeb H.H.; Mahmoud S.; Elkadeem M.; Shalby H.S.; Abd-Elsalam S.; Hepatitis C virus: Efficacy of new DAAs Regimens. Infect Disord Drug Targets 2019","journal-title":"Infect Disord Drug Targets"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1080\/10428190701732861","volume":"49","author":"Park B.B.","year":"2008","unstructured":"Park B.B.; Kim J.S.; Lee Y.Y.; Kang H.J.; Ryoo B.Y.; Kang J.H.; Kim H.Y.; Kim B.S.; Oh S.Y.; Kwon H.C.; Won J.H.; Kim K.; Park K.; Suh C.; Kim W.S.; Clinical characteristics and outcome for hepatitis C virus-positive diffuse large B-cell lymphoma. Leuk Lymphoma 2008,49(1),88-94","journal-title":"Leuk Lymphoma"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3892\/or.2012.1883","volume":"28","author":"Nishikawa H.","year":"2012","unstructured":"Nishikawa H.; Tsudo M.; Osaki Y.; Clinical outcome in diffuse large B-cell lymphoma with hepatitis C virus infection in the rituximab era: A single center experience. Oncol Rep 2012,28(3),835-840","journal-title":"Oncol Rep"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.canep.2015.04.004","volume":"39","author":"Chen Y.Y.","year":"2015","unstructured":"Chen Y.Y.; Huang C.E.; Liang F.W.; Lu C.H.; Chen P.T.; Lee K.D.; Chen C.C.; Prognostic impact of hepatitis C virus infection in patients with diffuse large B-cell lymphoma treated with immunochemotherapy in the context of a novel prognostic index. Cancer Epidemiol 2015,39(3),382-387","journal-title":"Cancer Epidemiol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s00277-016-2903-8","volume":"96","author":"Dlouhy I.","year":"2017","unstructured":"Dlouhy I.; Torrente M.\u00c1.; Lens S.; Rovira J.; Magnano L.; Gin\u00e9 E.; Delgado J.; Balagu\u00e9 O.; Mart\u00ednez A.; Campo E.; Forns X.; S\u00e1nchez-Tapias J.M.; L\u00f3pez-Guillermo A.; Clinico-biological characteristics and outcome of hepatitis C virus-positive patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Ann Hematol 2017,96(3),405-410","journal-title":"Ann Hematol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1007\/s00277-017-3129-0","volume":"96","author":"Tsutsumi Y.","year":"2017","unstructured":"Tsutsumi Y.; Nakayama C.; Kamada K.; Kikuchi R.; Kudo D.; Ito S.; Matsuoka S.; Shiratori S.; Yamamoto Y.; Naruse H.; Teshima T.; Efficacy and prognosis of antiviral therapy on hepatitis C following treatment of lymphoma in HCV-positive diffuse large-cell lymphoma. Ann Hematol 2017,96(12),2057-2061","journal-title":"Ann Hematol"},{"key":"ref=23","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/717951","author":"Tsutsumi Y.","year":"2011","unstructured":"Tsutsumi Y.; Ito S.; Ogasawara R.; Kudo K.; Tanaka J.; Asaka M.; Imamura M.; HCV virus and lymphoid neoplasms. Adv Hematol 2011","journal-title":"Adv Hematol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1002\/ijc.30372","volume":"139","author":"Hosry J.","year":"2016","unstructured":"Hosry J.; Mahale P.; Turturro F.; Miranda R.N.; Economides M.P.; Granwehr B.P.; Torres H.A.; Antiviral therapy improves overall survival in hepatitis C virus-infected patients who develop diffuse large B-cell lymphoma. Int J Cancer 2016,139(11),2519-2528","journal-title":"Int J Cancer"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.leukres.2014.11.015","volume":"39","author":"Chen T.T.","year":"2015b","unstructured":"Chen T.T.; Chiu C.F.; Yang T.Y.; Lin C.C.; Sargeant A.M.; Yeh S.P.; Liao Y.M.; Bai L.Y.; Hepatitis C infection is associated with hepatic toxicity but does not compromise the survival of patients with diffuse large B cell lymphoma treated with rituximab-based chemotherapy. Leuk Res 2015b,39(2),151-156","journal-title":"Leuk Res"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1093\/annonc\/mdu166","volume":"25","author":"Arcaini L.","year":"2014","unstructured":"Arcaini L.; Vallisa D.; Rattotti S.; Ferretti V.V.; Ferreri A.J.; Bernuzzi P.; Merli M.; Varettoni M.; Chiappella A.; Ambrosetti A.; Tucci A.; Rusconi C.; Visco C.; Spina M.; Cabras G.; Luminari S.; Tucci M.; Musto P.; Ladetto M.; Merli F.; Stelitano C.; d\u2019Arco A.; Rigacci L.; Levis A.; Rossi D.; Spedini P.; Mancuso S.; Marino D.; Bruno R.; Baldini L.; Pulsoni A.; Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. Ann Oncol 2014,25(7),1404-1410","journal-title":"Ann Oncol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"8447","DOI":"10.3748\/wjg.v22.i38.8447","volume":"22","author":"Merli M.","year":"2016","unstructured":"Merli M.; Carli G.; Arcaini L.; Visco C.; Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma. World J Gastroenterol 2016,22(38),8447-8458","journal-title":"World J Gastroenterol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1056\/NEJMoa013376","volume":"347","author":"Hermine O.","year":"2002","unstructured":"Hermine O.; Lefr\u00e8re F.; Bronowicki J.P.; Mariette X.; Jondeau K.; Eclache-Saudreau V.; Delmas B.; Valensi F.; Cacoub P.; Brechot C.; Varet B.; Troussard X.; Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002,347(2),89-94","journal-title":"N Engl J Med"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1182\/blood-2014-12-618652","volume":"125","author":"Sultanik P.","year":"2015","unstructured":"Sultanik P.; Klotz C.; Brault P.; Pol S.; Mallet V.; Regression of an HCV-associated disseminated marginal zone lymphoma under IFN-free antiviral treatment. Blood 2015,125(15),2446-2447","journal-title":"Blood"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1111\/apt.13825","volume":"44","author":"Economides M.P.","year":"2016","unstructured":"Economides M.P.; Mahale P.; Kyvernitakis A.; Turturro F.; Kantarjian H.; Naing A.; Hosry J.; Shigle T.L.; Kaseb A.; Torres H.A.; Concomitant use of direct-acting antivirals and chemotherapy in hepatitis C virus-infected patients with cancer. Aliment Pharmacol Ther 2016,44(11-12),1235-1241","journal-title":"Aliment Pharmacol Ther"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3322\/caac.21403","volume":"67","author":"Torres H.A.","year":"2017","unstructured":"Torres H.A.; Shigle T.L.; Hammoudi N.; Link J.T.; Samaniego F.; Kaseb A.; Mallet V.; The oncologic burden of hepatitis C virus infection: A clinical perspective. CA Cancer J Clin 2017,67(5),411-431","journal-title":"CA Cancer J Clin"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/ajh.23889","volume":"90","author":"Michot J.M.","year":"2015","unstructured":"Michot J.M.; Canioni D.; Driss H.; Alric L.; Cacoub P.; Suarez F.; Sibon D.; Thieblemont C.; Dupuis J.; Terrier B.; Feray C.; Tilly H.; Pol S.; Leblond V.; Settegrana C.; Rabiega P.; Barthe Y.; Hendel-Chavez H.; Nguyen-Khac F.; Merle-B\u00e9ral H.; Berger F.; Molina T.; Charlotte F.; Carrat F.; Davi F.; Hermine O.; Besson C.; ANRS HC-13 Lympho-C Study Group. Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B-cell non-Hodgkin lymphomas, ANRS HC-13 lympho-C study. Am J Hematol 2015,90(3),197-203","journal-title":"Am J Hematol"}],"container-title":["Current Cancer Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/181836","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T15:08:58Z","timestamp":1607612938000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/181836\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,4]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,9,4]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1568009620666200511084731","relation":{},"ISSN":["1568-0096"],"issn-type":[{"type":"print","value":"1568-0096"}],"subject":[],"published":{"date-parts":[[2020,9,4]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-01-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-28","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}